Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
NCT05526144
Recruiting
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It is more common in the military and Veteran population compared to the general US population. NASH may progress to end-stage liver disease and primary liver cancer, and hence there is critical need for effective treatment. The goal of this clinical trial is to test whether low dose thyroid hormone administered to Veterans diagnosed with NA... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/21/2025
Locations: Harry S. Truman Memorial, Columbia, MO, Columbia, Missouri
Conditions: Nonalcoholic Steatohepatitis, Liver Fibrosis
Register for Updates
Interdisciplinary Group Care for the Treatment of Endometriosis-associated Pain
NCT06549985
Recruiting
The goal of this clinical trial is to determine if Peer Empowered Endometriosis Pain Support (PEEPS), an 8-week interdisciplinary, integrative group care program, decreases pain interference in participants with endometriosis-associated chronic pelvic pain between the ages 18 and 48. The main question we aim to answer is: Is PEEPS more effective than Education in decreasing pain interference? Researchers will compare people receiving PEEPS plus usual care to those receiving Education plus usua... Read More
Gender:
FEMALE
Ages:
Between 18 years and 48 years
Trial Updated:
02/20/2025
Locations: WashU Medicine, Saint Louis, Missouri
Conditions: Endometriosis, Pelvic Pain
Register for Updates
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706
Recruiting
Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical sym... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2025
Locations: BVL Research- Missouri, Liberty, Missouri
Conditions: Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
Register for Updates
Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome
NCT05944562
Recruiting
The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, CPI-0209 will demonstrate efficacy and be worth of further study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome
Register for Updates
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
NCT06828055
Recruiting
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Viking Clinical Site #112, Kansas City, Missouri
Conditions: Weight Loss
Register for Updates
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Retina Research Institute, LLC, Saint Louis, Missouri
Conditions: Radiation Retinopathy, Visual Impairment
Register for Updates
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
NCT05659381
Recruiting
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: University of Kansas Cancer Center, Kansas City, Missouri
Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Register for Updates
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771
Recruiting
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/18/2025
Locations: Washington University at St. Louis, Saint Louis, Missouri
Conditions: Asthma
Register for Updates
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
ALL
Ages:
Between 1 day and 30 days
Trial Updated:
02/18/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Congenital Heart Disease in Children
Register for Updates
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
NCT06503809
Recruiting
Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets. This randomized controlled trial will test whether a very-low- carbohydrate ketogenic diet can effectively and safely improve blood sugar control in adults with type 1 diabetes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
NCT05471908
Recruiting
Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
02/17/2025
Locations: St. Louis Children's Hospital, Saint Louis, Missouri
Conditions: Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Register for Updates
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
Recruiting
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Saint Francis Medical Center, Cape Girardeau, Missouri
Conditions: Lung Non-Small Cell Carcinoma
Register for Updates